Amgen Could Block Enbrel Biosimilars For Another Decade As Court Rules Stealth Patents Valid

 
• By Brenda Sandburg
Tumor-necrosis
Court finds patents covering the TNF-IgG1 immunoglobulin fusion protein are valid.

More from Biosimilars

More from Biosimilars & Generics